EP2741771A4 - Methods and compositions for the treatment of autoimmune and inflammatory diseases - Google Patents
Methods and compositions for the treatment of autoimmune and inflammatory diseasesInfo
- Publication number
- EP2741771A4 EP2741771A4 EP20120821568 EP12821568A EP2741771A4 EP 2741771 A4 EP2741771 A4 EP 2741771A4 EP 20120821568 EP20120821568 EP 20120821568 EP 12821568 A EP12821568 A EP 12821568A EP 2741771 A4 EP2741771 A4 EP 2741771A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- autoimmune
- compositions
- treatment
- methods
- inflammatory diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 230000001363 autoimmune Effects 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
- C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161522009P | 2011-08-10 | 2011-08-10 | |
PCT/US2012/050146 WO2013023059A2 (en) | 2011-08-10 | 2012-08-09 | Methods and compositions for the treatment of autoimmune and inflammatory diseases |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2741771A2 EP2741771A2 (en) | 2014-06-18 |
EP2741771A4 true EP2741771A4 (en) | 2015-04-15 |
EP2741771B1 EP2741771B1 (en) | 2020-04-29 |
Family
ID=47669232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12821568.8A Active EP2741771B1 (en) | 2011-08-10 | 2012-08-09 | Methods and compositions for the treatment of autoimmune and inflammatory diseases |
Country Status (10)
Country | Link |
---|---|
US (3) | US9879092B2 (en) |
EP (1) | EP2741771B1 (en) |
JP (1) | JP6253580B2 (en) |
KR (2) | KR102101478B1 (en) |
CN (1) | CN104114184B (en) |
AU (1) | AU2012294342B2 (en) |
CA (1) | CA2844668C (en) |
ES (1) | ES2813415T3 (en) |
RU (1) | RU2639540C2 (en) |
WO (1) | WO2013023059A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
CN109793893B (en) | 2012-09-07 | 2023-05-26 | 达特茅斯大学理事会 | VISTA modulators for diagnosis and treatment of cancer |
US11447568B2 (en) * | 2014-04-10 | 2022-09-20 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of ocular diseases and disorders |
MX2018009800A (en) | 2016-02-12 | 2018-11-09 | Janssen Pharmaceutica Nv | Anti-vista (b7h5) antibodies. |
CA3020848A1 (en) | 2016-04-15 | 2017-10-19 | Janssen Pharmaceuticals, Inc. | Anti-human vista antibodies and use thereof |
US20200200760A1 (en) * | 2017-05-16 | 2020-06-25 | Lankenau Institute Of Medical Research | Compositions comprising ligands to rhob protein and the uses thereof |
KR102276941B1 (en) * | 2018-07-03 | 2021-07-14 | 서울대학교산학협력단 | Peptides for treating rheumatoid arthritis and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962672A (en) * | 1998-09-18 | 1999-10-05 | Isis Pharmaceuticals Inc. | Antisense modulation of RhoB expression |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993022332A2 (en) * | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US6458783B1 (en) * | 1997-09-29 | 2002-10-01 | Bristol-Myers Squibb Company | Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase |
CA2304473A1 (en) * | 1997-09-29 | 1999-04-22 | Rajeev S. Bhide | Inhibitors of farnesyl protein transferase |
US20050032733A1 (en) | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
EP1656156A2 (en) * | 2003-08-13 | 2006-05-17 | Children's Hospital Medical Center | Mobilization of hematopoietic cells |
JP4967137B2 (en) * | 2005-04-18 | 2012-07-04 | 国立大学法人浜松医科大学 | Cancer treatment composition |
US20070213354A1 (en) | 2006-03-08 | 2007-09-13 | Amplimed Corporation | Compositions and Methods for the Treatment of Multiple Sclerosis |
RU2489166C2 (en) * | 2006-04-09 | 2013-08-10 | Джинентех, Инк. | Using antibodies for treating autoimmune diseases in patient with inadequate response to tnf-alpha inhibitor |
JP5354634B2 (en) * | 2007-01-25 | 2013-11-27 | 国立大学法人大阪大学 | Human ABH8 protein, gene encoding it, and therapeutic or diagnostic uses thereof |
EP2221063A1 (en) | 2009-02-20 | 2010-08-25 | Ganymed Pharmaceuticals AG | Methods and compositions for diagnosis and treatment of cancer |
-
2012
- 2012-08-09 ES ES12821568T patent/ES2813415T3/en active Active
- 2012-08-09 AU AU2012294342A patent/AU2012294342B2/en active Active
- 2012-08-09 CN CN201280049868.XA patent/CN104114184B/en not_active Expired - Fee Related
- 2012-08-09 JP JP2014525142A patent/JP6253580B2/en active Active
- 2012-08-09 KR KR1020147006215A patent/KR102101478B1/en active IP Right Grant
- 2012-08-09 CA CA2844668A patent/CA2844668C/en active Active
- 2012-08-09 KR KR1020207010387A patent/KR102221068B1/en active IP Right Grant
- 2012-08-09 RU RU2014106933A patent/RU2639540C2/en not_active IP Right Cessation
- 2012-08-09 EP EP12821568.8A patent/EP2741771B1/en active Active
- 2012-08-09 WO PCT/US2012/050146 patent/WO2013023059A2/en active Application Filing
- 2012-08-09 US US14/237,706 patent/US9879092B2/en active Active
-
2017
- 2017-12-14 US US15/841,416 patent/US20180094076A1/en not_active Abandoned
-
2020
- 2020-09-03 US US17/011,852 patent/US20210040230A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962672A (en) * | 1998-09-18 | 1999-10-05 | Isis Pharmaceuticals Inc. | Antisense modulation of RhoB expression |
Non-Patent Citations (7)
Title |
---|
ANDRÉA SILVEIRA SANTOS-BREDARIOL ET AL: "Small GTP-binding protein RhoB is expressed in glial müller cells in the vertebrate retina", THE JOURNAL OF COMPARATIVE NEUROLOGY, vol. 494, no. 6, 20 February 2006 (2006-02-20), pages 976 - 985, XP055172812, ISSN: 0021-9967, DOI: 10.1002/cne.20861 * |
ANONYMOUS: "Rho B Antibody (C-5) | Santa Cruz Biotech", 1 January 2015 (2015-01-01), XP055172701, Retrieved from the Internet <URL:http://www.scbt.com/datasheet-8048-rho-b-c-5-antibody.html> [retrieved on 20150227] * |
JEAN-PIERRE SEGAIN ET AL: "Rho kinase blockade prevents inflammation via nuclear factor kappaB inhibition: Evidence in Crohn's disease and experimental colitis", vol. 124, no. 5, 1 May 2003 (2003-05-01), pages 1180 - 1187, XP002699002, ISSN: 0016-5085, Retrieved from the Internet <URL:http://www.sciencedirect.com/science/article/pii/S001650850300283X> [retrieved on 20150303], DOI: 10.1016/S0016-5085(03)00283-X * |
See also references of WO2013023059A2 * |
SUN X ET AL: "The selective Rho-kinase inhibitor Fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 180, no. 1-2, 1 November 2006 (2006-11-01), pages 126 - 134, XP027901570, ISSN: 0165-5728, [retrieved on 20061101] * |
WANG L ET AL: "A novel strategy for specifically down-regulating individual Rho GTPase activity in tumor cells", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 278, no. 45, 7 November 2003 (2003-11-07), pages 44617 - 44625, XP002312008, ISSN: 0021-9258, DOI: 10.1074/JBC.M308929200 * |
ZHAO DEZHENG ET AL: "Rho GTPases as therapeutic targets for the treatment of inflammatory diseases", EXPERT OPINION ON THERAPEUTIC TARGETS, INFORMA HEALTHCARE, GB, vol. 7, no. 5, 1 October 2003 (2003-10-01), pages 583 - 592, XP009182895, ISSN: 1744-7631 * |
Also Published As
Publication number | Publication date |
---|---|
KR102221068B1 (en) | 2021-02-25 |
US20210040230A1 (en) | 2021-02-11 |
ES2813415T3 (en) | 2021-03-23 |
RU2639540C2 (en) | 2017-12-21 |
US20140227279A1 (en) | 2014-08-14 |
KR20140067027A (en) | 2014-06-03 |
KR102101478B1 (en) | 2020-04-16 |
RU2014106933A (en) | 2015-09-20 |
US20180094076A1 (en) | 2018-04-05 |
EP2741771B1 (en) | 2020-04-29 |
JP6253580B2 (en) | 2017-12-27 |
JP2014529590A (en) | 2014-11-13 |
CN104114184B (en) | 2017-04-19 |
WO2013023059A2 (en) | 2013-02-14 |
KR20200042013A (en) | 2020-04-22 |
AU2012294342A1 (en) | 2014-03-06 |
EP2741771A2 (en) | 2014-06-18 |
AU2012294342B2 (en) | 2017-07-27 |
CA2844668C (en) | 2021-03-09 |
CN104114184A (en) | 2014-10-22 |
WO2013023059A3 (en) | 2013-04-04 |
CA2844668A1 (en) | 2013-02-14 |
US9879092B2 (en) | 2018-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL267014A (en) | Compositions and methods for treatment of autoimmune and other diseases | |
IL257581A (en) | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
TWI560200B (en) | Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders | |
EP2621499A4 (en) | Methods for the treatment of allergic diseases | |
ZA201308111B (en) | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor | |
HK1195312A1 (en) | Novel compound useful for the treatment of degenerative and inflammatory diseases | |
HUE041553T2 (en) | Methods and compositions for the treatment of monogenic diseases | |
EP2655334A4 (en) | Compositions and methods useful for treating diseases | |
EP2684167A4 (en) | Compositions and methods useful for treating diseases | |
EP2701742A4 (en) | Compositions and method for treating autoimmune diseases | |
IL229079A0 (en) | Methods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases | |
EP2771030A4 (en) | Compositions and methods for treatment of proteinopathies | |
EP3047024A4 (en) | Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders | |
ZA201408059B (en) | Compositions and methods for the treatment of inflammatory bowel disease | |
EP2544703A4 (en) | Methods of treating vascular inflammatory disorders | |
EP2633054A4 (en) | New compositions and methods for treatment of autoimmune and allergic diseases | |
EP2741771A4 (en) | Methods and compositions for the treatment of autoimmune and inflammatory diseases | |
EP2788012A4 (en) | Compositions and methods for treatment of kidney diseases | |
EP2575824A4 (en) | Methods for the treatment and prevention of inflammatory diseases | |
EP2709632A4 (en) | Compositions and methods for the treatment of skin diseases | |
ZA201408062B (en) | Compositions and methods for the treatment of multiple sclerosis | |
EP2780360A4 (en) | Compositions and methods for treating autoimmune and inflammatory disorders | |
EP2708233A4 (en) | Ctrp6 which can be used as therapeutic and prophylactic agent for autoimmune diseases | |
EP2556161A4 (en) | Methods for the treatment of autoimmune diseases | |
EP3603631C0 (en) | Methods and compositions for the treatment of diverticulosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140306 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20150312 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 5/071 20100101ALI20150306BHEP Ipc: C07K 16/40 20060101AFI20150306BHEP Ipc: A61K 39/395 20060101ALI20150306BHEP Ipc: A61K 38/00 20060101ALI20150306BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20170705 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20191119 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602012069732 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1263154 Country of ref document: AT Kind code of ref document: T Effective date: 20200515 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20200429 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200831 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200729 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200829 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200730 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1263154 Country of ref document: AT Kind code of ref document: T Effective date: 20200429 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200729 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602012069732 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2813415 Country of ref document: ES Kind code of ref document: T3 Effective date: 20210323 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
26N | No opposition filed |
Effective date: 20210201 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200831 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200831 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200809 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20200831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200831 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200809 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230921 Year of fee payment: 12 Ref country code: GB Payment date: 20230926 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230926 Year of fee payment: 12 Ref country code: DE Payment date: 20230925 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20230930 Year of fee payment: 12 |